2 Firms Guide HDL Therapeutics' $480M SPAC Merger
Heart-disease therapy maker HDL Therapeutics Inc. said Friday it has signed an agreement to merge with special-purpose acquisition company Swiftmerge Acquisition Corp. at an estimated $480 million valuation, guided by two...To view the full article, register now.
Already a subscriber? Click here to view full article